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Abstract
Background:  Stomach  cancer  (SC)  and  colorectal  cancer  (CRC)  present  with  high  rates  of  inci-
dence and  mortality  in  the  worldwide  population.  These  2  tumors  are  characterized  by  great
genetic heterogeneity.  Up  to  now,  there  have  been  no  molecular  studies  that  analyze  the
mutations in  the  APC, KRAS,  and  TP53  genes  in  the  Colombian/Latin  American  population.
Objectives:  To  analyze  mutations  in  the  APC,  KRAS,  and  TP53  genes  through  direct  sequencing
in 59  patients  with  SC  and  CRC.
Patients  and  methods:  Twenty-nine  patients  with  SC  and  30  with  CRC  were  studied.  An  analysis
of the  mutations  of  the  3  genes  was  carried  out  using  polymerase  chain  reaction  and  direct
sequencing  techniques.
Results:  A  30.5%  total  mutation  frequency  was  found.  The  most  frequently  mutated  gene  was
APC (15.3%),  followed  by  KRAS  (10.1%)  and  TP53  (5.1%).  The  CRC  samples  had  a  mutation
frequency  of  46.7%  and  it  was  13.3%  in  the  SC  samples  (P  =  .006).  No  mutations  occurred  simulta-
neously in  the  3  genes.  Mutations  in  2  genes  were  found  in  only  6  tumor  samples  (10%).  There  was
also a  high  frequency  of  polymorphisms  in  both  types  of  cancer,  the  most  common  of  which
was the  rs41115  polymorphism,  located  on  the  APC  gene.
Conclusion:  The  APC,  KRAS,  and  TP53  gene  mutations  were  more  common  in  CRC  than  in  SC.
Our results  suggest  the  existence  of  different  genetic  pathways  in  the  carcinogenesis  of  SC  and
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CRC  and  they  also  reveal  a  particular  mutation  frequency  in  the  Colombian  patients  studied;
this could  be  inﬂuenced  by  factors  related  to  the  environment,  ethnicity,  and  lifestyle  of  this
population.
© 2013  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.  All
rights reserved.
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Resumen
Antecedentes:  El  cáncer  de  estómago  (CE)  y  colorrectal  (CCR)  presentan  altas  tasas  de  inciden-
cia y  mortalidad  en  la  población  mundial.  Estas  2  neoplasias  se  caracterizan  por  tener  una  gran
heterogeneidad  genética.  Hasta  el  momento,  no  existen  estudios  moleculares  que  analicen  las
mutaciones  en  los  genes  APC, KRAS  y  TP53  en  población  colombiana/latinoamericana.
Objetivo:  Analizar  mutaciones  en  los  genes  APC,  KRAS  y  TP53  en  59  pacientes  con  CE  y  CCR
mediante  el  secuenciamiento  directo.
Pacientes  y  métodos:  Se  estudió  a  29  pacientes  con  CE  y  30  con  CCR.  Se  realizó  un  análi-
sis de  mutaciones  en  los  3  genes  por  las  técnicas  de  reacción  en  cadena  de  la  polimerasa  y
secuenciamiento  directo.
Resultados:  Se  encontró  una  frecuencia  total  de  mutaciones  del  30.5%.  El  gen  más  frecuente-
mente mutado  fue  APC  (15.3%),  seguido  de  KRAS  (10.1%)  y  TP53  (5.1%).  Las  muestras  de  CCR
presentaron  una  frecuencia  de  mutaciones  del  46,7%  y  las  CE  del  13.3%  (p  =  0.006).  No  se  encon-
traron mutaciones  simultáneas  en  los  3  genes.  En  solo  6  muestras  de  tumores  (10%)  se  detectaron
mutaciones  en  2  genes.  Adicionalmente,  se  obtuvo  una  alta  frecuencia  de  polimorﬁsmos  en
ambos tipos  de  cáncer,  el  más  común  fue  el  rs41115  localizado  en  el  gen  APC.
Conclusión:  Las  mutaciones  en  los  genes  APC,  KRAS  y  TP53  fueron  más  comunes  en  el  CCR
que en  el  CE;  nuestros  resultados  indican  la  existencia  de  diferentes  vías  genéticas  en  la  car-
cinogénesis  del  CE  y  del  CCR,  y  revelan  una  frecuencia  de  mutaciones  particular  en  los  pacientes
colombianos  estudiados,  que  podría  estar  inﬂuida  por  factores  ambientales  y  étnicos,  y  el  estilo
de vida  de  esta  población.
©  2013  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Todos los  derechos  reservados.
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tomach  cancer  (SC)  and  colorectal  cancer  (CRC)  have  high
ncidence  and  mortality  rates  in  the  world  population.1--3
he  situation  is  more  alarming  in  the  developing  countries
ecause  there  is  a  tendency  toward  increase  in  the  mortality
ate;  the  majority  of  cases  are  diagnosed  in  the  advanced
tages  and  have  a  poor  prognosis.4 Worldwide,  SC  is  the
ourth  cause  of  death  by  cancer  and  is  more  frequent  in
en  than  in  women.1 The  incidence  of  SC  varies  geographi-
ally.  There  is  a  high  incidence  rate  in  the  Asian  countries  of
orea,  Japan,  and  China,  as  well  as  in  some  Latin  American
ountries.1 In  Colombia,  SC  holds  second  place  in  incidence
n  men  and  women  and  it  is  the  ﬁrst  cause  of  death  by
ancer.1 More  than  90%  of  the  SC  cases  are  adenocarcino-
as  and  they  are  histologically  classiﬁed  as  2  types:  diffuse
nd  intestinal.5,6 There  are  multiple  etiologic  factors  in  the
athogenesis  of  SC  and  they  include  genetic,  environmental,
ietary,  and  lifestyle  factors,  as  well  as  bacterial  infection
ith  Helicobacter  pylori  (H.  pylori).7--9On  the  other  hand,  CRC  is  the  third  most  frequent  tumor
n  men  and  women  worldwide  and  the  highest  incidence
ates  are  found  in  the  developed  countries.1 In  Colombia,
t
a
tRC  holds  sixth  place  in  incidence  and  fourth  in  mortality,
n  both  sexes.1 Similar  to  that  observed  in  SC,  CRC  has  a
aried  geographic  distribution  with  genetic,  environmental,
thnic,  and  lifestyle  factors,  among  others,  involved  in  CRC
tiology.10 The  majority  of  CRC  cases  are  sporadic  and  a  low
ercentage  of  them  are  related  to  a  family  history  of  the
isease.11,12
In  Colombia,  SC  and  CRC  have  a  varied  geographic
istribution.  There  are  high  incidences  in  the  central,  north-
ast,  southern,  southeastern,  and  southwestern  regions  of
he  country,  whereas  low  incidences  are  observed  in  the
aribbean  (northern)  and  Paciﬁc  regions.  This  disparity
ould  be  due  to  dietary  habits  that  include  the  different
ypes  of  home-cooked  foods  high  in  nitrites  that  are  typical
f  each  region  and  a  high  consumption  of  smoked  red  meats,
s  well  as  to  alcohol  ingestion  and  smoking.6
SC  and  CRC  are  very  heterogeneous  diseases  that  orig-
nate  through  different  genetic  pathways.  Chromosomal
lterations,  oncogenic,  tumor  suppressing  gene,  and  repair
ene  mutations,  and  methylation  in  the  genes  that  control
he  cell  cycle  are  common.13--15 Particularly  in  CRC,  Fearon
nd  Vogelstein  proposed  a molecular  model  that  describes
he  sequence  of  colorectal  carcinogenesis  from  adenoma  to
mac
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sGenetic  analysis  in  APC,  KRAS, and  TP53  in  patients  with  sto
carcinoma,  in  which  there  are  mutations  in  different  onco-
genes  and  tumor-suppressing  genes.14
On  the  other  hand,  genetic  studies  in  SC  and  CRC  report
that  APC, KRAS, TP53, CDH1, MLH1, and  ERBB2  gene  alter-
ations  are  among  the  most  common  molecular  changes
acquired  in  the  carcinogenesis  of  these  2  malignancies.2,16--20
Thus  it  is  proposed  that  these  genes  are  essential  for  the
transformation  of  normal  cells  into  carcinoma.  And  so  the
molecular  characterization  of  the  genetic  pathways  of  SC
and  CRC  are  of  great  importance  for  their  later  correla-
tion  with  the  clinical  and  pathologic  characteristics  and  with
patient  outcome.21--23
In  this  study,  we  formulated  the  hypothesis  that  the
mutation  frequency  in  the  APC, KRAS, and  TP53  genes  in
the  SC  and  CRC  samples  from  Colombian  patients  is  different
from  that  of  other  populations.
The  aim  of  our  study  was  to  analyze  the  somatic  muta-
tions  in  the  APC, KRAS, and  TP53  genes  through  direct
sequencing  in  Colombian  patients  presenting  with  stomach
cancer  and  colorectal  cancer.
Methods
Population  and  sample
A  cross-sectional  descriptive  study  was  conducted.  The
study  population  was  made  up  of  59  patients,  29  presenting
with  SC  and  30  with  CRC,  all  of  which  were  of  the  sporadic
type.  The  study  included  27  women  and  32  men.  None  of
the  patients  had  a  history  of  cancer  nor  had  they  received
antineoplastic  treatment  prior  to  surgery.  All  the  SC  and
CRC  cases  were  conﬁrmed  through  histopathologic  study.
The  patients  were  asked  to  voluntarily  participate  in  the
study  and  they  signed  statements  of  informed  consent.  The
study  protocol  was  approved  by  the  Bioethics  Committee
of  the  Universidad  de  Antioquia,  Medellín,  Colombia,  for
experimentation  on  humans.
The  samples  of  the  primary  tumor  tissues  were  obtained
by  the  surgeons  through  surgical  resection  at  2  health  insti-
tutions  in  Medellín,  Colombia:  the  Hospital  Universitario
San  Vicente  Fundación  and  the  Clínica  León  XIII  within  the
time  frame  of  2010  to  2011.  Each  of  the  tumor  samples  was
divided  into  2  portions,  one  for  histopathologic  study  per-
formed  by  an  expert  pathologist  and  the  other  stored  at
--80 ◦C  for  later  genetic  analysis.
DNA  extraction
DNA  extraction  from  the  primary  tumor  tissue  was  carried
out  using  the  commercial  QIAamp  DNA  Mini  Kit  (Qiagen,
Hilden,  Germany),  following  the  manufacturer’s  recommen-
dations.  The  DNA  was  then  quantiﬁed  in  a  NanoDrop  2000c
Spectrophotometer  (Thermo  Scientiﬁc,  USA)  determining
its  integrity  through  1%  agarose  gel  electrophoresis.  The
extracted  DNA  was  stored  at  --20 ◦C.
DNA  ampliﬁcation  and  the  APC,  KRAS,  and  TP53
gene mutation  analysis
The  isolated  DNA  was  ampliﬁed  through  the  polymerase
chain  reaction  (PCR)  method  in  a  Gene  Amp  PCR  System
p
a
wh  and  colon  cancer  81
700  thermocycler  (Applied  Biosystems,  USA),  using  speciﬁc
rimers  for  each  gene.  The  mutation  cluster  region  (MCR)
ocated  in  exon  15  was  ampliﬁed  in  the  APC  gene;  exon  2
codons  12  and  13)  was  ampliﬁed  in  the  KRAS  gene;  and
xons  5  to  8  were  ampliﬁed  in  the  TP53  gene.  In  short,  the
CR  was  done  at  a  volume  of  35  l  containing  300  ng  of  tumor
NA  in  a reagent  mixture  at  the  following  concentrations:
x  for  the  10x  reaction  buffer,  200  M  of  dNTPs,  0.4  M  of
ach  primer,  and  1.4  U  of  Taq  DNA  polymerase  (Invitrogen,
SA).  The  MgCl2 concentrations  were  1.05  mM  for  APC  and
RAS  and  1.5  mM  for  TP53. The  PCR  ampliﬁcation  products
ere  examined  through  2%  agarose  gel  electrophoresis  and
tained  with  ethidium  bromide;  they  were  stored  at  --20 ◦C
ntil  sequencing.
equencing
ll  the  ampliﬁed  samples  were  puriﬁed  and  both  chains
ere  directly  sequenced.  Sequencing  was  performed  with
n  automatic  3730xl  DNA  Analyzer  from  Applied  Biosystems.
esult  analysis
he  chromatograms  obtained  were  edited  with  the  Chro-
as  Pro  program  and  were  aligned  with  the  reference
equences  published  in  the  GenBank  (NCBI)  whose  access
odes  are:  NT  034772.6  (APC), NT  009714.17  (KRAS),  and
T  010718.16  (TP53).
tatistical  analysis
he  results  were  analyzed  using  the  SPSS  version  18  pro-
ram.  In  the  descriptive  statistics,  means  and  ranges  were
mployed  for  the  quantitative  variables  and  the  categorical
ariables  were  presented  in  frequencies  and  percentages.
he  Pearson  chi-square  test  was  used  for  the  comparison  of
ategorical  variables  such  as  sex  and  mutation  frequency;
hen  the  expected  values  were  lower  than  5,  the  Yates
orrection  was  employed.  The  comparison  between  the  con-
inuous  quantitative  variables,  like  age,  was  carried  out  with
he  Student’s  t test  for  independent  samples.  All  the  calcu-
ated  p  values  were  bilateral  and  a  value  of  p  <  0.05  was
onsidered  statistically  signiﬁcant.
esults
 total  of  59  patients  with  a  mean  age  of  64.1  years  (range
2-94)  were  studied.  Patients  with  CRC  and  SC  were  strat-
ﬁed  by  age  and  sex.  The  mean  age  of  the  ﬁrst  group  was
2.1  years  (range  12-84)  and  the  mean  age  of  the  second
roup  was  66.1  years  (range  36-94).  No  signiﬁcant  difference
as  observed  between  the  2  groups  (p  =  0.332).  In  relation  to
ex,  63.3%  of  the  patients  presenting  with  CRC  were  women
nd  36.7%  were  men,  whereas  27.6%  of  the  patients  with  SC
ere  women  and  72.4%  were  men.  There  was  a  statistically
igniﬁcant  difference  between  the  2  groups  (p  =  0.005).Among  the  most  common  signs  and  symptoms  that
atients  with  SC  presented  were:  epigastric  pain,  emesis,
sthenia,  adynamia,  anorexia,  nausea,  anemia,  bleeding,
eight  loss,  and  bowel  obstruction.  The  most  frequent
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ymptoms  of  the  CRC  patients  were:  rectal  bleeding,  weight
oss,  bowel  obstruction,  constipation,  diffuse  abdominal
ain,  melena,  and  abdominal  bloating.
The  total  mutation  frequency  in  the  59  samples  analyzed
as  30.5%  (18/59)  (Table  1).  In  addition,  a  high  frequency
f  polymorphisms  was  found  in  the  3  genes,  identifying  a
otal  of  7  different  polymorphisms  in  the  59  samples;  the
ost  frequent  was  the  rs41115  (c.4479G  >  A,  p.Thr1493Thr)
olymorphism,  located  in  exon  15  of  the  APC  gene.  All  the
olymorphisms  identiﬁed  in  this  study  are  reported  in  the
NP  database.24
Only  one  mutation  in  the  APC  gene  (3.5%)  was  found  in
he  SC  samples;  this  mutation  was  a  deletion  of  2  nucleotides
AG)  in  the  c.4393 4394delAG  position,  which  produces  a
remature  stop  codon  in  the  protein  (p.Ser1465ArgfsX9)
Table  1).  In  these  same  samples,  the  rs41115  polymor-
hism  was  also  identiﬁed,  with  a  high  frequency  of  86.2%
25/29)  (Table  2)  (Fig.  1).  In  contrast,  the  frequency  of  the
utations  identiﬁed  in  the  APC  gene  was  26.6%  (8/30)  in
he  CRC  samples.  Four  of  these  mutations  were  frameshift
utations  and  the  other  4  were  point  mutations;  Table  1
escribes  the  detected  mutations  in  more  detail  (Fig.  1).
pon  comparing  the  mutation  frequency  in  the  APC  gene,
 tendency  toward  a  greater  frequency  in  CRC  than  in  SC
as  found  (p  =  0.06).  Furthermore,  2  polymorphisms  were
dentiﬁed  in  these  samples:  the  rs41115  polymorphism  with
 frequency  of  56.7%  (17/30)  and  the  rs1801166  polymor-
hism  (c.3949G  >  C,  p.Glu1317Gln)  with  a  frequency  of  3.3%
1/30)  (Table  2).
On  the  other  hand,  the  mutation  frequency  in  the
RAS  gene  was  6.9%  (2/29)  in  the  SC  samples  (Table  1).
he  mutations  were  2  base  substitutions  that  occurred  in
odons  12  and  13;  both  mutations  produced  a  change  in
he  protein  sequence:  c.35G  >  A  (p.Gly12Asp)  and  c.38G  >
 (p.Gly13Asp)  (Table  1,  Fig.  1).  In  addition,  2  polymor-
hisms  in  intron  2  were  identiﬁed;  the  most  frequent  was
he  rs12228277  polymorphism  (c.111  +  190  A  > T)  in  27.6%  of
he  samples  (8/29)  (Table  2).  The  other  was  the  rs61759635
olymorphism  (c.111  +  116  111  +  120delTAACT);  it  was  iden-
iﬁed  in  only  one  sample  (3.5%)  and  consisted  of  a  deletion  of
 nucleotides.  The  mutation  frequency  of  the  KRAS  gene  in
he  CRC  samples  was  13.3%  (4/30)  (Table  1);  all  the  detected
utations  were  base  substitutions:  3  in  codon  12  and  one  in
odon  13  (Table  1).  No  differences  were  found  upon  com-
aring  the  mutation  frequency  in  the  KRAS  gene  between
he  SC  and  CRC  samples  (p  =  0.69).  Just  as  in  the  genetic
nalysis  of  the  KRAS  gene  in  the  SC  samples,  2  polymor-
hisms  with  a  high  frequency  of  40%  (12/30)  were  identiﬁed
n  the  CRC  samples;  the  most  frequent  was  the  rs12228277
olymorphism  with  36.7%  (11/30),  whereas  the  rs61759635
olymorphism  presented  in  3.3%  (1/30)  (Table  2).
Finally,  a  mutation  frequency  in  the  TP53  gene  of
.5%  (1/29)  was  found  in  the  SC  samples  (Fig.  1).  The
.517G  >  A  (p.Val173Met)  mutation  was  detected  in  exon
 (Table  1).  Moreover,  3  polymorphisms  were  identiﬁed:  the
s1800372  polymorphism  (c.639A  >  G,  p.Arg213Arg)  in  exon
 with  a  frequency  of  3.5%  and  2  polymorphisms,  rs12947788
c.782  +  72C  >  T)  and  rs12951053  (c.782  +  92T  >  G),  in  intron
,  co-segregating  together,  with  a  frequency  of  17.2%  (5/29)
Table  2).  Similarly  to  that  found  in  the  SC  samples,  2  (6.6%)
utations  in  this  gene  were  identiﬁed  in  the  CRC  samples
p  = 0.98);  both  mutations  were  base  substitutions  in  exon  6
t
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nd  they  produced  a  premature  stop  codon  (Table  1).  Once
gain,  2  polymorphisms  in  intron  7  were  identiﬁed,  with  a
requency  of  16.7%  (5/30)  of  the  cases  (Table  2).
In  relation  to  the  histology  of  the  SC  cases,  the  intestinal
ype  was  the  most  common,  with  48.3%  (14/29),  followed  by
he  diffuse  type,  with  41.4%  (12/29);  half  of  the  cases  were
ound  to  present  with  advanced  stages  of  the  cancer  (III  and
V),  the  majority  in  stage  III.  Of  this  group  of  patients,  20.7%
ad  metastases.  The  4  mutations  identiﬁed  in  the  SC  samples
resented  in  the  intestinal  adenocarcinomas,  which  had  an
dvanced  stage  of  malignancy  (stage  IV).  The  location  of
he  SC  cases  was  mainly  in  the  antrum,  with  58.6%  (17/29)
Table  3).
Regarding  the  CRC  cases,  almost  half  the  cases  were  in  an
dvanced  stage  of  the  cancer,  with  the  majority  in  stage  IV.
f  the  13  cases  with  mutations  in  the  3  genes,  the  high  per-
entage  of  77%  (10/13)  were  identiﬁed  in  well  differentiated
denocarcinomas.  Stage  IV  was  the  most  common  in  these
ases  (7/13).  The  mutations  were  more  frequently  located
n  the  descending  colon  (9/13),  followed  by  the  ascending
olon  (3/13)  (Table  4).
In  summary,  the  results  showed  a  greater  total  mutation
requency  in  the  APC, KRAS, and  TP53  genes  in  the  CRC  sam-
les  (46.7%)  than  in  the  SC  samples  (13.3%)  (p  =  0.006).  In
he  59  tumor  samples  analyzed,  no  simultaneous  mutations
ere  identiﬁed  in  the  3  genes;  only  6  tumors  (10%)  had  muta-
ions  in  2  genes,  distributed  as  follows:  in  the  CRC  samples,
 tumors  had  simultaneous  mutations  in  the  APC-KRAS  genes
nd  2  tumors  had  them  in  the  APC-TP53  genes,  whereas  only
ne  case  in  the  SC  samples  had  mutations  in  the  APC-KRAS
enes.
Lastly,  in  this  study  a high  frequency  of  polymorphisms
as  found  with  no  differences  between  the  patients  with  SC
nd  CRC  (p  =  0.108).  The  total  polymorphism  frequency  for
he  APC, KRAS, and  TP53  genes  in  the  59  tumor  samples  was
4.6%,  35.6%,  and  35.6%,  respectively  (Table  2).
iscussion
his  is  the  ﬁrst  study  in  Latin  America  analyzing  the  muta-
ions  in  the  APC, KRAS, and  TP53  genes  and  conducted  on
9  patients  with  stomach  cancer  (SC)  and  colorectal  cancer
CRC).  A  total  of  18  (30.5%)  of  the  59  samples  had  mutations.
The  mutation  frequency  in  the  3  genes  analyzed  was
ound  to  be  greater  in  the  CRC  samples  than  in  the  SC
amples.  These  results  are  consistent  with  those  of  other
uthors11,25 that  reported  a  higher  frequency  of  APC, KRAS,
nd  TP53  gene  mutations  in  CRC,  according  to  the  model  pro-
osed  by  Fearon  and  Volgestein  in  the  adenoma-carcinoma
equence.13,21 On  the  other  hand,  our  results  in  the  SC  sam-
les  showed  that  mutations  in  these  3  genes  were  unusual,
imilar  to  that  reported  in  other  studies.3,5,26,27 It  could  thus
e  suggested  that  SC  and  CRC  develop  by  means  of  dif-
erent  genetic  pathways,  such  as  chromosomal  alterations,
icrosatellite  instability,  different  gene  promoter  methyl-
tion,  and  alterations  in  other  genes  directly  related  to
reater  SC  risk.In  this  study,  of  the  3  genes  analyzed,  the  APC  gene  was
he  most  frequently  mutated  in  the  CRC  samples,  whereas
t  had  a  low  mutation  frequency  in  the  SC  samples;  how-
ver,  this  difference  was  not  statistically  signiﬁcant.  This
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Table  1  Mutations  identiﬁed  in  the  APC,  KRAS,  and  TP53  genes  in  the  SC  and  CRC  samples  analyzed.
Tumor Gene  Case  No. Exon  Codon  Position Mutation  Amino  acid  change %  Mutation
Stomach  APC  08  15  1465  c.4393 4394  del  AG AGAGAG→AGAG p.Ser1465TrpfsX3 3.3
KRAS 04  2  12  c.35G>A  GGT→GAT p.Gly12Asp  6.7
08 2  13  c.38G>A  GGC→GAC p.Gly13Asp
TP53 017  5  173  c.517G>A  GTG→ATG p.Val173Met 3.5
Colorectal APC  031  15  1465  c.4393 4394dupAG AGAG→AGAGAG p.Ser1465ArgfsX9  26.7
032 15  1367  c.4099C>T  CAG→TAG p.Gln1367X
037, 039 15  1556  c.4666dupA  AAC→AAAC p.Thr1556AsnfsX3
38 15  1443  c.4329T>A  CCA→CCT p.Pro1443Pro
15 1474  c.4420A>G  ACT→GCT p.  Ala1474Thr
052 15  1306  c.3916G>T  GAA→TAA p.Glu1306X
053 15  1309  c.3927 3931delAAAGA AAAAGAAAAGA→AAAAGA p.Glu1309AspfsX4
KRAS 031,  037 2  12  c.35G>A  GGT→GAT p.Gly12Asp  13.3
033 2  12  c.35G>T  GGT→GTT p.Gly12Val
053 2  13  c.38G>A  GGC→GAC p.Gly13Asp
TP53 032  6  188  c.562C>T  c.563T>A CTG→TAG p.Leu188X  6.7
039 6  199  c.595G>T  GGA→TGA p.Gly199X
Upon comparing the APC mutation frequency between SC and CRC (p = 0.006).
Upon comparing the KRAS mutation frequency between SC and CRC (p = 0.06).
Upon comparing the TP53 mutation frequency between SC and CRC (p = 0.98).
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Table  2  The  polymorphisms  identiﬁed  in  the  APC,  KRAS,  and  TP53  genes  in  the  59  samples  of  the  SC  and  CRC  patients  evaluated.
Gene  Exon/Intron  SNP  code  Change  in
the  protein
cDNA  CRC  SC  p
No.  %  No.  %
APC  Exon  15 rs41115  p.T1493T  c.4479G>A  18  60  25  86.2  0.008a
rs1801166  p.Glu1317Gln  c.3949G>C  1  3.3  -  -
KRAS Intron  2  rs61759635  -  c.111  +  116  111
+ 120delAGTTA
1  3.3  1  3.5  0.4b
rs12228277  -  c.111  +  190A>T  11  37  8  27.6
TP53 Exon  6  rs1800372  p.Arg213Arg  c.639A>G  -  -  1  3.5  0.69c
Intron  7  rs12947788  -  c.782  +  72C>T  5  17  5  17.2
rs12951053  -  c.782  +  92T>G  5  17  5  17.2
TOTAL 41 -  45  -
SNP: Single nucleotide polymorphism; **CRC: Colorectal cancer; *** SC: Stomach cancer.
a Upon comparing the APC polymorphism frequency between SC and CRC.
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c Upon comparing the TP53 polymorphism frequency between S
nding  is  similar  to  the  results  reported  by  Lee  et  al.,  who
ound  a  frequency  of  2.5%  in  the  analysis  of  237  SC  sam-
les  in  patients  in  Korea28 and  to  those  of  Horii  et  al.  and
amashita  et  al.  who  reported  frequencies  of  6.8%  and  3.4%,
espectively.3,29 These  collective  results  indicate  that  muta-
ions  in  the  APC  gene  are  not  common  in  SC;  likewise,  these
tudies  suggest  a  negative  relation  between  mutations  in  the
PC  gene  and  the  development  of  SC,  which  concurs  with
ther  studies  reporting  that  APC  gene  mutations  are  rare
n  extracolonic  neoplasias.  Different  genetic  pathways  have
een  described  in  relation  to  the  carcinogenesis  of  SC,  such
s  chromosomal  instability  (CIN),  microsatellite  instability
MSI  that  occurs  between  30  and  40%),  ˇ-catenin  muta-
ions,  and  APC, MLH1, and  RPRM  gene  methylation.3,6,14,15,30
f
o
w
g
A  BAPC: Exon 15, C AG  → TAG 
C  DTP53: Exon 5, TGC → TTC
C>T
G>T
igure  1  Direct  sequencing  chromatograms  showing  the  different  i
) Mutation  in  KRAS  identiﬁed  in  SC  and  CRC  samples.  C)  Mutation  
etected with  a  high  frequency  in  SC  and  CRC  patients.  The  arrows   CRC.
 CRC.
n  the  other  hand,  in  regard  to  SC  carcinogenesis,  other
on-genetic  factors  should  be  taken  into  account  that
nclude  diet,  especially  high  red  meat  consumption,  smoked
oods,  and  those  preserved  with  salt,  the  exposure  to  certain
nvironmental  agents,  and  H.  pylori  infection,  given  that
his  infection  has  a  prevalence  of  up  to  85%  in  the  Colombian
opulation.10
Contrastingly,  in  the  CRC  samples,  there  was  a  greater
utation  frequency  in  the  APC  gene.  However,  the  fre-
uency  reported  in  our  study  (26.7%)  was  lower  than  that
ound  by  other  authors  who  report  a  mutation  frequency
f  up  to  60%  when  the  entire  coding  region  of  the  gene
as  analyzed.11,19,31,32 We  only  analyzed  exon  15  of  the  APC
ene,  where  the  MCR  region  is  found,  and  where  the  greater
KRAS: Exon 2, GGT → GAT
APC: Exon 15, ACG → ACA
G>A
G>A
dentiﬁed  mutations.  A)  Mutation  in  APC  found  in  a  case  of  CRC.
in  TP53  found  in  a  case  of  SC.  D)  T1493  polymorphism  in  APC
show  the  site  of  the  base  change.
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Table  3  General  description  of  the  clinical  and  pathologic  characteristics  and  the  mutation  frequency  in  the  29  SC  patients  analyzed.
Total,  n  (%) APC  KRAS  TP53
Normal
n  (%)
Mutated
n  (%)
Normal
n  (%)
Mutated
n  (%)
Normal
n  (%)
Mutated
n  (%)
Number  of  patients 29  28  (96,6) 1  (3,4) 28  (93,3) 2  (6,7) 28  (93,3) 2  (6,7)
Age (mean) 65.5 66.1 64  67.8 70  66.5 65
Sex
Women 8 (27.5) 7  (24.1) 1  (3.4) 7  (24.1) 1  (3.4) 8  (26.7) -
Men 21  (72.4) 21  (72.4) -  20  (69) 1  (3.4) 20  (69) 1  (3.4)
SC stage
I 2  (6.9) 2  (6.9) -  2  (6.9) -  2  (6.9) -
II 12  (41.4)  12  (40)  -  12  (40)  - 12  (40)  -
III 9  (31)  9  (31)  -  8  (27.6)  1  (3.4)  8  (27.6)  1  (3.4)
IV 5  (17.2)  4  (13.8)  1  (3.4)  5  (16.7)  1  (3.4)  5  (16.7)  1  (3.4)
Not classiﬁed 1  (3.3) 1  (3.3) -  1  (3.3) -  1  (3.3)  -
Histologic type
Intestinal  adenocarcinoma  14  (48.3)  13  (44.8)  1  (3.4)  12  (41.4)  2  (6.9)  13  (44.8)  1  (3.4)
Diffuse adenocarcinoma  12  (41.4)  12  (41.4)  -  12  (41.4)  - 12  (41.4)  -
Mixed adenocarcinoma  3  (10.35)  3  (10.35)  -  3  (10.35)  - 3  (10.35)  -
Tumor location
Fundus  3  (10.35)  3  (10.35)  -  3  (10.35)  - 2  (6.9)  1  (3.4)
Body 9  (31)  9  (31)  -  9  (31)  - 9  (31)  -
Antrum 17  (58.6)  16  (55.2)  1  (3.4)  15  (51.7)  2  (6.9)  17  (58.6)  -
Metastasis
Yes 6  (20.7)  5  (16.7)  1  (3.4)  5  (16.7)  1  (3.4)  6  (20.7)  -
No 22  (75.9)  22  (75.9)  -  21  (72.4)  1  (3.4)  21  (72.4)  1  (3.4)
Not determined  1  (3.4)  1  (3.4)  -  1  (3.4)  - 1  (3.3)  -
SC: Stomach cancer.
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Table  4  General  description  of  the  clinical  and  pathologic  characteristics  and  the  mutation  frequency  in  the  30  sporadic  CRC  patients  analyzed.
APC  KRAS  TP53
n  (%)  Normal
n  (%)
Mutated
n  (%)
Normal
n  (%)
Mutated
n  (%)
Normal
n  (%)
Mutated
n  (%)
Number  of  patients  30  23  (76.7)  7  (23.3)  26  (86.7)  4  (13.3)  28  (93.3)  2  (6.6)
Age (mean) 62  56  56  63  59  62.5  53
Sex
Women 19  (63.3)  12  (40)  7  (23.3)  15  (50)  4  (13.3)  17  (56.7)  2  (6.6)
Men 11  (36.7)  11  (36.7)  -  11  (36.7)  -  11  (36.7)  -
CRC stage
I  3  (10)  2  (6.6)  1  (3.3)  3  (10)  -  3  (10)  -
II 10  (33.3)  8  (26.7)  2  (6.6)  8  (26.7)  2  (6.6)  10  (33.3)  -
III 2  (6,6)  2  (6,6)  -  2  (6,6)  -  2  (6,6)  -
IV 10  (33.3)  6  (20)  4  (13.3)  9  (30)  1  (3.3)  8  (26.7)  2  (6.6)
Not classiﬁed  5  (16.7)  5  (16.7)  -  4  (13.3)  1  (3.3)  5  (16.7)  -
Histologic type
Well  differentiated  adenocarcinoma  17  (56.7)  12  (40)  5  (16.7)  13  (43.3)  4  (13.3)  16  (53.3)  1  (3.3)
Moderately differentiated  adenocarcinoma  7  (23.3)  6  (20)  1  (3.3)  7  (23.3)  -  6  (20)  1  (3.3)
Mucinous adenocarcinoma  2  (6.6)  2  (6.6)  -  2  (6,6)  -  2  (6.6)  -
Neuroendocrine carcinoma  2  (6.6)  1  (3.3)  1  (3.3)  2  (6.6)  -  2  (6.6)  -
Other 2  (6.6)  2  (6.6)  -  2  (6.6)  -  2  (6.6)  -
Tumor location
Ascending  6  (20)  4  (13.3)  2  (6.6)  5  (16.7)  1  (3.3)  6  (20)  -
Transverse 3  (10)  3  (10)  -  2  (6.6)  1  (3.3)  3  (10)  -
Descending 16  (53.3)  11  (36.7)  (16.7)  14  (46.7)  2  (6.6)  14  (46.7)  2  (6.6)
Rectum 4  (13.3)  4  (13.3)  -  4  (13.3)  -  4  (13.3)  -
Not classiﬁed  1  (3.3)  1  (3.3)  -  1  (3.3)  -  1  (3.3)  -
Metastasis
Yes 12  (40)  8  (26.7)  4  (13.3)  11  (36.7)  1  (3.3)  10  (33.3)  2  (6.6)
No 15  (50)  12  (40)  3  (10)  12  (40)  3  (10)  15  (50)  -
Not determined  2  (6.6)  -  2  (6.6)  -  2  (6.6)  2  (6.6)  -
*CRC: Colorectal cancer.
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FGenetic  analysis  in  APC,  KRAS, and  TP53  in  patients  with  sto
mutation  frequency  occurred.  It  must  also  be  kept  in  mind
that  population  differences  have  been  reported  in  relation
to  APC  mutation  frequency,  possibly  due  to  ethnic  compo-
sition,  sample  size,  mutations  outside  the  MCR  region,  and
other  APC  genetic  alterations  such  as  large  deletions  and  the
loss  of  heterozygosity  (LOH)  in  the  5q21  region.2,11,33,34
Furthermore,  a  low  mutation  frequency  in  the  KRAS  gene
was  found  in  the  SC  and  CRC  samples  analyzed.  The  fre-
quency  reported  for  SC  concurred  with  those  reported  in
the  literature,  which  are  in  a  range  from  0  to  10%.35--37 In
the  Asian  population,  which  has  a  high  incidence  of  SC,  low
mutation  frequencies  in  the  KRAS  gene  were  also  reported.35
Thus,  mutations  in  the  KRAS  gene  are  considered  to  be  very
rare  in  SC.  In  the  CRC  samples,  the  mutation  frequency  found
was  lower  than  had  been  expected  (13.3%);  a  mutation  fre-
quency  from  26  to  50%  is  reported  in  the  literature.31,38,39
Nevertheless,  the  mutation  frequency  reported  in  our  study
was  similar  to  that  found  by  Akkiprik  et  al.  in  43  samples  of
sporadic  CRC,  which  was  12%.18 A  high  mutation  frequency
of  the  KRAS  gene  has  been  observed  in  colorectal  adeno-
mas;  in  addition,  it  has  been  found  that  the  mutations  could
be  lost  through  selection  in  the  cells  that  progress  from
adenoma  to  carcinoma.31,40
With  respect  to  the  TP53  gene  mutations,  a  low  mutation
frequency  was  found  in  CRC  and  SC  that  was  within  the  range
reported  in  the  literature.41 However,  in  the  CRC  samples,
the  frequency  reported  in  this  study  was  surprisingly  low,
compared  with  reports  in  other  populations,  which  were  up
to  50%42 when  the  entire  coding  region  of  the  gene  was  ana-
lyzed.  We  only  evaluated  codons  5  through  8,  which  is  the
region  in  which  the  greatest  percentage  of  mutations  has
been  identiﬁed.43 Nevertheless,  the  presence  of  mutations
in  the  exons  that  were  not  evaluated  cannot  be  excluded.
The  differences  in  the  reported  frequencies  could  also  be
due  to  exposure  to  given  carcinogenic  agents  that  induce
speciﬁc  mutations  in  the  TP53  gene  and  to  other  genetic
alterations  common  to  this  gene,  such  as  microdeletions  and
LOH  in  the  17p.13.1  locus.3,20,42,44--46
In  the  genetic  analysis  of  the  CRC  samples  (25  from  the
colon  and  4  from  the  rectum),  our  study  revealed  that  all
the  detected  mutations  occurred  in  the  colon,  and  most  fre-
quently  in  the  descending  colon.  In  contrast,  no  mutations
were  found  in  the  cancer  samples  from  the  rectum,  possibly
due  to  the  low  number  of  tumors  analyzed.
In  addition,  no  simultaneous  mutations  in  the  3  genes
analyzed  were  found  in  the  SC  or  CRC  samples;  this  result
concurs  with  those  of  other  studies.11,12,47 This  simultaneous
mutation  is  regarded  as  an  infrequent  event,  especially  in
cases  of  sporadic  CRC  in  which  these  genes  have  been  widely
studied,  reporting  a  mutation  frequency  for  them  under
7%.11,12,47 Concomitant  mutations  in  2  genes  were  found  in
only  6  cases  (10.2%)  and  the  APC  and  KRAS  gene  combina-
tion  was  the  most  frequent;  these  results  are  similar  to  those
reported  in  other  studies.12 It  could  therefore  be  suggested
that  the  mutations  in  the  APC  and  KRAS  genes  occur  in  the
early  stages  of  CRC,  favoring  cancer  progression.12 In  rela-
tion  to  the  sporadic  CRC  carcinogenesis  model,  it  is  posited
that  the  accumulation  of  mutations  in  these  3  genes  is  not  a
prerequisite  for  the  development  of  many  sporadic  CRCs,  as
shown  in  our  study  and  in  those  of  other  authors,  and  that
at  least  one  third  of  the  CRCs  do  not  follow  this  sequential
model.11,12,47 Therefore,  it  is  proposed  that  the  APC, KRAS,
T
M
gh  and  colon  cancer  87
nd  TP53  gene  mutations  occur  through  independent  genetic
athways.12,18,19
Finally,  contrary  to  the  low  mutation  frequencies  found
n  the  APC, KRAS, and  TP53  genes  in  the  SC  and  CRC  samples,
e  found  a  high  frequency  of  polymorphisms  in  the  3  genes
nalyzed  in  our  study.  Of  the  7  polymorphisms  identiﬁed  in
he  59  study  samples,  the  most  frequent  was  the  rs41115
olymorphism  in  the  APC  gene.  The  high  frequencies  of
his  polymorphism  found  in  the  SC  (86.2%)  and  the  CRC  (60%)
amples  may  be  the  highest  reported  up  to  now  in  these
ypes  of  cancer.  All  the  polymorphisms  identiﬁed  in  our  study
re  reported  in  the  literature  and  in  the  SNP  database  of  the
CBI.24,48--52 The  association  of  these  polymorphisms  with  the
isk  for  developing  cancer  is  not  yet  well  deﬁned.53
The  rs41115  polymorphism  has  been  identiﬁed  in  dif-
erent  tumors,48,49,54--57 particularly  in  families  presenting
ith  familial  adenomatous  polyposis  (FAP),  and  it  has  been
bserved  to  cosegregate  with  germline  mutations  in  the
PC  gene;  therefore  it  is  suggested  that  the  individuals  in
amilies  with  FAP  could  be  at  greater  risk  for  developing
RC.50 On  the  other  hand,  this  ﬁrst  time  identiﬁcation  of
he  polymorphisms  reported  in  our  study  is  very  important
n  relation  to  the  genetic  component  of  the  Colombian  pop-
lation.  This  population  has  historically  been  regarded  as
 genetic  isolate  composed  of  an  ethnic  mixture  of  Euro-
eans  in  its  majority,  followed  by  Africans,  and  then  to  a
esser  degree,  Amerindians;58 thus,  these  genetic  variants
ould  make  up  part  of  the  genetic  composition  characteris-
ic  of  this  population.  Future  studies  with  a  greater  number
f  samples  are  needed  to  validate  these  results,  as  well  as  to
larify  the  association  of  the  identiﬁed  polymorphisms  with
he  risk  for  developing  SC  and  CRC.
In  summary,  this  is  the  ﬁrst  study  analyzing  the  APC,
RAS,  and  TP53  gene  mutations  in  patients  with  SC  and
RC  conducted  in  Latin  America.  Our  results  provide  impor-
ant  information  in  relation  to  the  genetic  component  of
he  Colombian  population  from  the  pattern  of  mutations
nd  polymorphisms  in  these  3  genes.  The  results  of  this
tudy  conﬁrm  previous  reported  data  on  the  mutation  fre-
uencies  in  SC,  but  they  differ  considerably  with  those
ound  in  CRC,  especially  those  in  the  TP53  gene.  And  ﬁnally,
ifferent  genetic  pathways  such  as  the  MSI,  CIN,  and  the
pigenetic  pathway  are  described  in  the  carcinogenesis  of
C  and  CRC.3,6,14,15,30
onclusions
he  APC, KRAS, and  TP53  gene  mutation  frequencies  were
reater  in  the  CRC  samples  than  in  the  SC  samples;  our
esults  suggest  that  there  are  different  genetic  pathways
n  the  carcinogenesis  of  SC  and  CRC  and  they  reveal  a  pat-
ern  of  mutations  and  polymorphisms  that  is  particular  to
he  Colombian  patients  studied.
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